QP Declaration for IMPs: some Questions and Answers
Recommendation
5-7 November 2024
Hamburg, Germany
GMP and FDA Compliance in Pharmaceutical Development and IMP Manufacturing
The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) Inspectorate has published a set of Question and Answers on the manufacture of Investigational Medicinal Products (IMPs) in a blog. Quite a few questions are dealing with the import of IMPs and the associated QP Declarations which accompany clinical trial (CT) applications.
Here is an overview:
Extend:
"All sites involved in manufacturing steps starting with the conversion of the API into the dosage form and including primary and secondary packing and also any contract laboratories involved with release or stability testing" should appear on the QP declarations.
Regulatory inspection instead of own audit:
"The starting point for a QP declaration of EU GMP should be an audit conducted by or on behalf of the importing company. (…). A regulatory inspection cannot be used unconditionally to remove the need for your own audit."
Audit by QP or not:
"An audit does not need to be done by the QP, however the QP needs to be satisfied that it has been done correctly by an appropriately trained individual as the QP will be taking final responsibility."
Recognition of Certification by Swiss QP (Responsible Person, RP)
"Although there is a Mutual Recognition Agreement (MRA) between the EU and Switzerland, it remains a third country therefore the IMP would need to be imported into the EU by an MIA(IMP) holder. (…) and the IMP would need to be certified by a (EU) QP upon import prior to release for use in the clinical trial."
QP statements for APIs used in IMPs
"There is no requirement for APIs used in IMPs to comply with EU GMP Part II but there remains a responsibility for IMP manufacturers to assure themselves that the API is of an appropriate quality."
Further details and more frequently asked questions can be found in the MHRA Inspectorate Blog.
Related GMP News
17.10.2024FDA's final Q&A Document on Electronic Systems & Data in Clinical Trials
17.10.2024EMA Guideline on Quality and Equivalence of Topical Products
05.09.2024Clinical Trials Regulation - Version 6.9 of the Q&As
23.07.2024Pilot Results on Regulatory-Led RWE Generation
23.07.2024ICH M12 Guideline on Drug Interaction Studies
20.06.2024Draft ICH M14 Guideline on Real-World Data for Safety Assessment